Skip to main content

Mood subdued in Germany, says VCI

30th August 2024

Submitted by:

Andrew Warmington

Germany’s chemical industry trade association, the VCI, said that the mood in the nation’s chemical and pharmaceutical industry “cooled noticeably in August because the global economy did not pick up as hoped”. This applies particularly to chemicals. “A weak industrial economy in Europe, the USA and China, as well as a lack of price-competitiveness in Germany, are dampening sales opportunities abroad,” the VCI said.

Chemical exports declined in almost all regions in 1H, Asia excepted. Expectations for the coming months are also cautious. Pharmaceutical exports, particularly to North America and Asia, were much stronger, rising by 13%. This is expected to continue in the coming months.

The association also noted that R&D budgets continue to grow, rising by 4% to around €15.5 billion in 2023. Again, this was mainly driven by pharma, with chemical R&D budgets under pressure. For this year, a total R&D spend of about €15.5 billion is expected.

Germany’s attraction as a location is declining, due to “structural problems, excessive bureaucracy, lengthy approval procedures and complicated project funding systems”, the VCI noted. As a result, companies are increasingly interested in research elsewhere and other countries are catching up. In addition, the German government lacks a coherent innovation strategy. “In other countries, costs are lower, public funding programmes are better and bureaucracy is lower,” said Thomas Wessel (pictured), chairman of the VCI research committee.

It is estimated that firms spend 5% of their man-hours filling out forms. With the growing importance of cross-sector innovations in chemical research and industrial application, the association noted, it is highly advantageous for innovators and customers to be close to each other geographically. Germany has an excellent scientific landscape, able researchers and strong basic research but this is wasted without a “comprehensive, one-stop innovation strategy”.

“A new funding programme here, a new institute there – it’s a patchwork. This development is reinforced by uncoordinated measures by the federal government and its departments,” said Wessel. He particularly highlighted the large cuts in federal funding for battery research planned for 2025.

The research committee advocated that the funding landscape should be financed from a combination of state funding, tax measures, institutional and private venture capital. Pilot and demonstration plants as well as real-world laboratories must also be funded in order to close the transfer gap between basic and applied research. Finally, much more must be done to address the shortage of skilled workers.

Feature article – Saltigo rides out the cycle

Market and sustainability trends are positive drivers for Saltigo, despite the agro downturn. Andrew Warmington met up with the new CEO at Chemspec Europe

Submitted by:

Andrew Warmington

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical active ingredient (AI) manufacturing to its wholly owned subsidiary UPL Spec

Submitted by:

Andrew Warmington

Nippon Shokubai opens Indonesian plant

Japan’s Nippon Shokubai has officially opened a 100,000 tonnes/year acrylic acid (AA) plant that was built at a cost of about $200 million at Cilegon, Banten, Indonesia.

Submitted by:

Andrew Warmington

CABB to invest at Finnish agro site

The CABB Group has said that it will invest over €50 million by 2025 to expand facilities at its agrochemical manufacturing site in Kokkola, Finland.

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production planning of superabsorbent polymers (SAPs) based on acrylic acid, and has started operati

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after a week after the latter declined to engage with it.

Submitted by:

Andrew Warmington

adcs

Three invest further into ADCs

Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.

Submitted by:

Andrew Warmington

Cambrex exits drug product

CDMO Cambrex has sold its Drug Product business unit to Noramco. Terms were not disclosed.

Submitted by:

Andrew Warmington

Siegfried breaks ground on R&D centre

Siegfried has broke ground for its new global R&D centre for drug substances at its site in Evionnaz, Switzerland.

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants under the trade names AmphiCare and AmphiClean.

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based subsidiary of Seqens.

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in Austria have co-developed a computer-assisted regression model to improve enzyme performance and

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU and the Bio-based Industries Consortium (BIC) that funds projects advancing competitive circular bi

Submitted by:

Andrew Warmington

Investment in Tanasote plant

Octowood, a part of the Sweden’s Rundvirke Industrier Group, has invested in a new treatment plant using Arxada’s wood preservative, Tanasote.

Submitted by:

Andrew Warmington

Rhamnolipid milestone reached

Evonik has manufactured the first product from its industrial-scale biosurfactants facility at Slovenská Lupca in Slovakia.

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach Group in a move that it said would “create a global pigment company, combining SCIL’s ope

Submitted by:

Andrew Warmington

Lanxess to continue pigment production

Lanxess has reversed a decision to sell the chromium oxide pigments business at the Krefeld-Uerdingen site in Germany, preserving 50 jobs there.

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw materials, has announced a strategic collaboration with Japan’s Takasago, a large player in th

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site in Guangzhou. This triples its manufacturing capacity for fragrances and establis

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable fragrance ingredients from renewable carbon, with US-based LanzaTech, which describes i

Submitted by:

Andrew Warmington

Kao boosts jasmine fragrance

Japan's Kao Corporation is to double capacity for the synthetic fragrance methyl dihydrojasmonate (MDJ) at its site in Olesa, Spain, by adding a second production facility.

Submitted by:

Andrew Warmington

Merck KGaA “in a strong strategic position”

At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitio

Submitted by:

Andrew Warmington

Suez joins Global Impact Coalition

Suez, which describes itself as “a global leader in circular solutions for water and waste”, has joined the Global Impact Coalition (GIC).

Submitted by:

Andrew Warmington

Chemours opens battery lab

Chemours has opened Chemours Battery Innovation Centre (CBIC) at the Chemours Discovery Hub in Newark, Delaware.

Submitted by:

Andrew Warmington